RESULTS OF ANTIEPILEPTIC DRUG REDUCTION IN PATIENTS WITH MULTIPLE HANDICAPS AND EPILEPSY

被引:27
作者
MIRZA, WU [1 ]
CREDEUR, LJ [1 ]
PENRY, JK [1 ]
机构
[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,MED CTR,WINSTON SALEM,NC 27517
来源
DRUG INVESTIGATION | 1993年 / 5卷 / 06期
关键词
D O I
10.1007/BF03259239
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the treatment of patients with epilepsy who are mentally retarded and have multiple handicaps has generally involved polypharmacy, there is an emerging trend towards simplified antiepileptic drug (AED) regimens. A prospective study of reduction in the number of AEDs was conducted in an institutionalised population of profoundly retarded patients with epilepsy and multiple handicaps. Of 44 patients with uncontrolled generalised seizures who were receiving 4 or 5 AEDs in our study, 28 (64%) achieved monotherapy and the remaining 16 (36%) achieved duotherapy, with significantly improved seizure control and reduced intensity of seizures (although seizure frequency increased transiently in some patients following withdrawal of primidone and phenobarbital). 14 patients (32%) became seizure-free: 13 received monotherapy and 1 received duotherapy. The remaining patients had greater-than-or-equal-to 50% reduction in seizure frequency while receiving monotherapy (15 of 28) or duotherapy (15 of 16). The majority of patients who became seizure-free were receiving divalproex sodium or a combination of divalproex and phenytoin. After dosage reduction to regimens with 1 or 2 drugs, most patients showed more positive behaviours and became more sociable. Overall treatment costs were also markedly reduced. We conclude that AED reduction to mono- or duotherapy is desirable in patients with multiple handicaps and refractory seizures who are receiving polypharmacy regimens.
引用
收藏
页码:320 / 326
页数:7
相关论文
共 27 条
[1]  
Albright P., Bruni J., Reduction of polypharmacy in epileptic patients, Archives of Neurology, 42, pp. 797-799, (1985)
[2]  
Armour D.J., Veitch G.B.A., Is valproate monotherapy a practical possibility in chronically uncontrolled epilepsy?, Journal of Clinical Pharmacy and Therapeutics, 13, pp. 53-64, (1988)
[3]  
Beghi E., Bollini P., Di Mascio R., Cerisola N., Merloni T., Et al., Effects of rationalizing drug treatment of patients with epilepsy and mental retardation, Developmental Medicine and Child Neurology, 29, pp. 363-369, (1987)
[4]  
Bourgeois B., Beaumanoir A., Blajev B., de la Cruz N., Despland P.A., Et al., Monotherapy with valproate in primary generalized epilepsies, Epilepsia, 28, pp. 8-11, (1987)
[5]  
Chadwick D., Comparison of monotherapy with valproate and other antiepileptic drugs in the treatment of seizure disorders, American Journal of Medicine, 84, pp. 3-6, (1988)
[6]  
Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice, Epilepsia, 27, pp. 323-330, (1986)
[7]  
Behavioral and cognitive effects of anticonvulsant therapy, Pediatrics, 76, pp. 644-647, (1985)
[8]  
Cornaggia C., Canevini M.P., Giuccioli D., Pinelli P., Pruneri C., Et al., Monotherapy and polytherapy for intractable epilepsies, Italian Journal of Neurological Sciences, 6, pp. 201-205, (1985)
[9]  
Covanis A., Gupta A.K., Jeavons P.M., Sodium valproate: monotherapy and polytherapy, Epilepsia, 23, pp. 693-720, (1982)
[10]  
Dean J.C., Penry J.K., Valproate monotherapy in 30 patients with partial seizures, Epilepsia, 29, pp. 140-144, (1988)